InsidersTradesSigma
Follow the ZimVie Inc. stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, ZimVie Inc. has logged 83 public disclosures. The latest transaction was reported on 20 October 2025 (Disposition). Among the most active insiders: Jamali Vafa. Every trade is free.
83
Insider Decl.
n/a
Thresholds
€1m
7 ops.
Buy Volume
€54m
8 ops.
Sell Volume
24Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 20 October 2025
Declarations83 total
40,127 sharesCommon StockSEC:0001193125-25-243820:0
83,674 sharesCommon StockSEC:0001193125-25-243713:0
63,438 sharesCommon StockSEC:0001193125-25-243829:0
389,152 sharesCommon StockSEC:0001193125-25-243730:0
125,389 sharesCommon StockSEC:0001193125-25-243767:0
40,794 sharesCommon StockSEC:0001193125-25-243795:0
1,057 shares@ US$18.935.4% of flowCommon StockSEC:0001909313-25-000003:0
145 shares@ US$9.614.1% of flowCommon StockSEC:0001062993-25-012548:0
11,127 shares0Common StockSEC:0001062993-25-009782:0
8,063 shares0Common StockSEC:0001062993-25-009780:0
10,966 shares0Common StockSEC:0001062993-25-009779:0
48,379 shares0Common StockSEC:0001062993-25-009778:0
16,127 shares0Common StockSEC:0001062993-25-009776:0
21,331 shares0Common StockSEC:0001062993-25-006967:0
3,999 shares@ US$13.085.6% of flowCommon StockSEC:0001062993-25-006392:0
90,065 shares0Common StockSEC:0001062993-25-006391:0
11,377 shares0Common StockSEC:0001062993-25-005150:0
90,065 shares0Common StockSEC:0001062993-25-005148:0
15,170 shares0Common StockSEC:0001062993-25-005149:0
24,650 shares0Common StockSEC:0001062993-25-005151:0
6,542 shares0Common StockSEC:0001062993-25-005152:0
4,126 shares@ US$13.085.8% of flowCommon StockSEC:0001062993-25-004287:0
1,058 shares@ US$15.705.0% of flowCommon StockSEC:0001062993-24-017243:0
525,000 shares@ US$17.7131100.0% of flowCommon StockSEC:0001654954-24-010034:0
147 shares@ US$18.188.9% of flowCommon StockSEC:0001062993-24-013319:0
25 of 83 declarations
关于 ZimVie Inc.
ZimVie Inc. 是一家总部位于美国的医疗器械公司，在美国纳斯达克上市。该公司于 2022 年 3 月作为 Zimmer Biomet 的独立公开分拆公司成立，将原有的牙科和脊柱业务整合到一个独立的结构下。ZimVie 总部位于佛罗里达州棕榈滩花园，通过全球商业足迹和世界各地的其他设施，历来为 70 多个国家的客户提供服务。([investor.zimvie.com](https://investor.zimvie.com/news-releases/news-release-details/zimvie-report-fourth-quarter-and-full-year-2024-financial/?utm_source=openai)) 在业务线方面，ZimVie 以其牙科种植学和修复牙科解决方案而闻名。其产品组合包括牙科种植体、修复组件、愈合基台、生物材料和数字工作流程解决方案，供牙科专业人士、种植外科医生、实验室和分销商使用。公司的产品定位于牙齿替换和修复程序，重点是临床支持的差异化平台。ZimVie 在分拆后的早期也曾拥有脊柱业务，但该部门已于 2024 年 4 月出售并关闭，使公司更专注于牙科业务。([investor.zimvie.com](https://investor.zimvie.com/news-releases/news-release-details/zimvie-report-fourth-quarter-and-full-year-2024-financial/?utm_source=openai)) 从竞争角度来看，ZimVie 在一个由大型、资金雄厚的竞争对手组成的全球市场中作为专业参与者运营。因此，其投资案例一直围绕产品差异化、临床证据、国际分销和投资组合重点，而非仅仅规模。在剥离脊柱业务后，管理层强调了更精简的结构，并将资本和注意力更多地集中在牙科特许经营权上。这种战略调整对股票投资者很重要，因为它使 ZimVie 成为一家更专注于牙科的公司，而不是其曾经更广泛的肌肉骨骼和牙科平台。([investor.zimvie.com](https://investor.zimvie.com/news-releases/news-release-details/zimvie-announces-closing-sale-spine-business?utm_source=openai)) 最近的公司新闻尤其重要。2025 年 7 月，ZimVie 宣布与 ARCHIMED 的关联公司达成最终协议，以每股 19.00 美元的现金价格被收购。2025 年 10 月，股东批准了该交易，ZimVie 随后宣布收购已完成，此后公司成为私有企业。对于在纳斯达克追踪 ZIMV 的市场参与者而言，这是该时期的一个决定性事件，并实质性地改变了公司的公开市场地位、所有权结构和战略前景。([investor.zimvie.com](https://investor.zimvie.com/news-releases/news-release-details/zimvie-announces-definitive-agreement-be-acquired-archimed-1900?utm_source=openai))
